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ABSTRACT
Objective To determine whether use of cannabis in
adolescence increases the risk for psychotic outcomes by
affecting the incidence and persistence of subclinical
expression of psychosis in the general population (that is,
expression of psychosis below the level required for a
clinical diagnosis).
Design Analysis of data from a prospective population
based cohort study in Germany (early developmental
stages of psychopathology study).
Setting Population based cohort study in Germany.
Participants 1923 individuals from the general
population, aged 14-24 at baseline.
Main outcome measure Incidence and persistence of
subthreshold psychotic symptoms after use of cannabis
in adolescence. Cannabis use and psychotic symptoms
were assessed at three time points (baseline, T2
(3.5 years), T3 (8.4 years)) over a 10 year follow-up period
with the Munich version of the composite international
diagnostic interview (M-CIDI).
Results In individuals who had no reported lifetime
psychotic symptoms and no reported lifetime cannabis
use at baseline, incident cannabis use over the period
from baseline to T2 increased the risk of later incident
psychotic symptoms over the period from T2 to T3
(adjusted odds ratio 1.9, 95% confidence interval 1.1 to
3.1; P=0.021). Furthermore, continued use of cannabis
increased the risk of persistent psychotic symptoms over
the period from T2 to T3 (2.2, 1.2 to 4.2; P=0.016). The
incidence rate of psychotic symptoms over the period
frombaseline to T2was 31% (152) in exposed individuals
versus 20% (284) in non-exposed individuals; over the
period from T2 to T3 these rates were 14% (108) and 8%
(49), respectively.
Conclusion Cannabis use is a risk factor for the
development of incident psychotic symptoms. Continued
cannabis use might increase the risk for psychotic
disorder by impacting on the persistence of symptoms.
INTRODUCTION
Cannabis is the most commonly used illicit drug in the
world, particularly among adolescents.1 2 The use of
cannabis is consistently associated with mental
illness,3 in particular psychotic disorder.4-9 It remains
a matter of debate, however, whether the association
between cannabis and psychosis is causal, or whether
early psychotic experiences might in fact prompt can-
nabis use as a means of self medication.10 11 This issue
can be resolved only if incident cannabis use is investi-
gated in relation to later incident psychotic symptoms
or disorder. Rarely have studies been able to examine
the longitudinal relation between cannabis use and
psychosis in this fashion.
The issue of self medication was addressed by
Henquet and colleagues,6 using data from the German
prospective early developmental stages of psycho-
pathology study.12 13 The authors investigated the asso-
ciation between cannabis use at baseline and
subsequent development of psychotic symptoms at
four year follow-up and reported that after adjustment
for pre-existing psychotic symptoms, cannabis use at
baseline still remained significantly associated with
psychotic symptoms at follow-up. There was no evi-
dence of an effect of selfmedication as pre-existing psy-
chotic symptoms did not significantly predict later
cannabis use.6 Ferdinand and co-workers investigated
the role of pre-existing self reported psychotic symp-
toms and showed a bi-directional association between
cannabis and psychotic symptoms over a 14 year fol-
low-up study in the general population.11 They showed
that cannabis use predicted later psychotic symptoms
in individuals with no evidence of psychotic symptoms
before starting to use cannabis and that the reverse was
also true, in that psychotic symptoms predicted canna-
bis use in those who had not used cannabis before the
onset of those symptoms.11 A prospective population
based cohort study also found evidence for a self med-
ication effect.14 Individuals with self reported halluci-
nations at the age of 14 had a higher risk of using
cannabis on a daily basis at the age of 21. In a sibling
pair analysis, however, this study also suggested an
independent effect of cannabis use on self reported
delusional ideation later in life.14 Thus, although the
cannabis-psychosis link has been investigated in
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many studies, results on the temporal association
between cannabis use and psychotic symptoms remain
conflicting. Longitudinal cohort studies with multiple
repeated interviewbasedmeasures of cannabis use and
psychotic symptoms are needed to clarify this issue.
The EDSP study,12 13 which completed its recent
10 year follow-up representing the fourth assessment
(assessments at baseline, T1, T2, and T3, see also fig 1),
is uniquely suitable for the investigation of the tem-
poral association between cannabis and psychosis.
Another issue is the mechanism by which cannabis
might increase the risk of psychotic symptoms, parti-
cularly whether it might increase the risk by causing
persistence of normally transitory developmental
expression of psychotic experiences. For most indivi-
duals, subclinical expression of psychotic phenomena
(that is, expression of psychosis below the level
required for a clinical diagnosis) is transitory and
never progresses to psychotic illness.15 Subthreshold
psychotic experiences could, however, become abnor-
mally persistent, dependingon the degree of additional
exposure to environmental risk factors,16-18 and pro-
gressively greater levels of persistence might be asso-
ciated with a greater risk for transition to clinical
psychotic disorder.19 Spauwen and colleagues showed
that the persistence rate of psychotic experiences was
much higher for individuals growing up in an urban
rather than a rural environment.16 Similarly,Cougnard
and co-workers provided evidence that childhood
trauma, urban environment, and cannabis act addi-
tively in increasing the risk of persistence of psychotic
experiences.17 The fact that cannabis use increases risk
of psychosis in a dose-response fashion614 20 and that
patients with psychosis who continue to use cannabis
show more severe and persistent symptoms21 suggests
that cannabis use might increase the risk for psychotic
illness by impacting on the persistence rate of psycho-
tic experiences that under normal circumstances (that
is, without exposure to cannabis)would have remained
transitory phenomena formost people. In a population
based 10 year follow-up cohort study of adolescents
and young adults, we investigated the association
between incident cannabis use and true incidence of
psychotic experiences (that is, after exclusion of indivi-
duals with lifetime pre-existing psychotic experiences)
and risk of persistence of psychotic experiences.
METHOD
Sample and study design
The observation frame was part of the early develop-
mental stages of psychopathology (EDSP) study,
which collected data on the prevalence, incidence,
risk factors, comorbidity, and course of mental disor-
ders in a random representative population sample of
adolescents and young adults in the general
population.12 13 After ethical approval, the baseline
sample was randomly drawn in 1994 from the respec-
tive population registry offices of Munich and its 29
counties to mirror the distribution of individuals aged
14-24 at the time of the baseline interview in 1995. The
base population comprised people born from 1 June
1970 to 31 May 1981 registered as residents in these
localities and having German citizenship. These regis-
ters are highly accurate because each German is regis-
tered by his or her town, registers are regularly
updated, for scientific studies any number of randomly
drawn addresses with a given sex and age group can be
Baseline T2
3.5 years
T3
8.4 years
Cannabis continuation Persistence of psychotic experiences
Baseline T2 T3
Incident cannabis use Incident psychotic experiences
Fig 1 |Study design. Top: testing association between incident cannabis use with onset in
period from baseline to T2 and incident psychotic symptoms with onset in period from T2 to T3
in individuals who had not used cannabis at baseline and who had not reported any psychotic
experience at T2 (that is, no lifetime psychotic experiences by T2). Bottom: testing association
between different cannabis exposure states (combinations of cannabis use at baseline
(lifetime), or T2 or both (interval) and persistence of psychotic experiences (that is, presence of
psychotic experiences at both T2 (lifetime) and T3 (interval))
Table 1 | Characteristics of participants by use of cannabis at
T2 (3.5 years after baseline) (n=1923). Figures are numbers
(percentages)
Used cannabis
(n=393)
Did not use cannabis
(n=1530)
Men 119 (30) 807 (53)
Women 274 (70) 723 (47)
Socioeconomic status*:
Lower 30 (7) 85 (6)
Middle 220 (54) 894 (59)
Upper 137 (34) 524 (35)
Other 22 (5) 6 (0.4)
Urban/rural environment†:
Urban 295 (75) 1050 (69)
Rural 98 (25) 480 (31)
Childhood trauma‡:
Yes 97 (25) 266 (17)
No 296 (75) 1264 (83)
Use of other drugs at baseline§:
Yes 25 (6) 11 (1)
No 368 (94) 1519 (99)
Use of other drugs at T2§:
Yes 40 (10) 3 (0.2)
No 353 (90) 1527 (99)
Any psychiatric disorder at baseline**¶:
Yes 76 (19) 180 (12)
No 317 (81) 1350 (88)
*Socioeconomic status: lower (lower class, lower middle class), middle
(middle middle class), upper (higher middle class, upper class), other
(none of the above or missing). Data missing for five participants.
†Urban (city of Munich, 10 559/km2), rural (surroundings of Munich,
1432/km2).
‡Childhood trauma: any traumatic experience during childhood.
§On more than five occasions.
¶Other than psychosis, according to M-CIDI diagnoses.
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obtained, and registration is strictly enforced by law
and the police.More details on the sampling, represen-
tativeness, instruments, procedures, and statistical
methods of the study sample can be found
elsewhere.12 13
The overall design of study is longitudinal and pro-
spective, consisting of a baseline and three follow-up
surveys. The first (baseline to T1) covered a mean of 1.
6 years (SD 0.2), the second (baseline to T2) covered a
mean of 3.5 years (SD 0.3), and the third (baseline to
T3) covered a mean of 8.4 years (range 7.3-10.5, SD
0.7). Because our primary goalwas to examine the inci-
dence and developmental risk factors for psycho-
pathology, we sampled the younger group (age 14-
15), presumed to have the highest incidence density,
at twice the rate of people aged 16-21 and sampled
the oldest group (age 22-24) at half this rate. For the
same reason we examined people aged 14-17 at base-
line at the four time points and those aged 18-24 only
three times (baseline, T2, T3). The present study is
based on the whole cohort assessed at baseline, T2,
and T3. Figure 1 shows a schematic illustration of the
overall design and the current analyses. Response rates
were 84% (2548) at T2 and 73% (2210) at T3 (fig 2).
Instruments
Weused the computerised version of theMunich com-
posite international diagnostic interview (DIA-X/M-
CIDI),22 anupdatedversionof theWorldHealthOrga-
nization’sCIDI version 1.2.23 TheDIA-X/M-CIDI is a
comprehensive fully standardised diagnostic interview
that assesses symptoms, syndromes, and diagnoses of
variousmental disorders in accordancewith the defini-
tions and criteria of ICD-10 (international classifica-
tion of diseases, 10th revision) and DSM-IV
(Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition), along with information about
onset, duration, severity of symptoms, and psychoso-
cial impairment. The CIDI has been primarily
designed for use in epidemiological studies of mental
disorders and can also be used for clinical purposes. It
is divided into 16 sections: one sociodemographic sec-
tion, 12 sections assessing 288 symptoms of groups of
mental disorders (including somatoform and dissocia-
tive, phobic and other anxiety, depressive and dysthy-
mic, manic and bipolar affective, schizophrenia and
other psychotic, eating, dementia and other cognitive,
post-traumatic stress, as well as tobacco, alcohol, and
substance related disorders), and three final sections
containing concluding questions, interviewers’ obser-
vations, and interviewers’ ratings. The instrument,
designed for use by trained interviewers who are not
clinicians, has shown high inter-rater24 25 and test-retest
reliability.22 26 The assessment of psychosis with CIDI
by lay interviewers is not considered reliable so trained
clinical interviewers at the level of clinical psycholo-
gist, whowere allowed to probe with follow-up clinical
questions, conducted the interviews in the respon-
dents’ homes. At baseline, the DIA-X/M-CIDI life-
time version was used. At each of the follow-up
assessments, the interval version was used to assess
the period from the last interview until the next. Data
on the G section concerning psychosis and its clinical
relevance were collected only at T2 (lifetime version)
and T3 (interval version). As the assessment of sub-
stance use was part of the diagnostic interview with
the DIA-X/M-CIDI, psychologists who did the inter-
views were not blinded for cannabis use.
Assessment of psychotic symptoms
Data on psychotic experiences were collected at time
T2 (lifetime version) and T3 (interval version) with the
G section of the DIA-X/M-CIDI. As the primary
objective of the EDSP study was to investigate the
early stages of substance misuse in adolescents and
young adults, data on the occurrence of psychotic
symptoms as assessed with the G section were added
at T2 (measuring lifetime experience of psychotic
symptoms) and T3 (measuring interval experience of
psychotic symptoms).13 As in previous work619 pre-
sence of psychotic experiences was broadly defined
as any rating of present on any of the 20 DIAX/M-
CIDI core psychosis items (G1, G2a, G3-G5, G7-
G13, G13b, G14, G17, G18, G20, G20C, G21, and
G22a), including 14 delusion items, five hallucination
items, and one item on passivity phenomena. Items
relate to classic psychotic symptoms involving, for
example, persecution, thought interference, auditory
hallucinations, and passivity phenomena. The
Baseline sample (n=3021)
Loss to follow-up (refusal to participate, failure
to contact individual, lack of time) (n=473)
T2 (3.5 year follow-up) (n=2548, 84%)
T3 (8.4 year follow-up) (n=2210, 73%)
Individuals with missing information (n=287)
Loss to follow-up (refusal to participate, failure
to contact individual, lack of time) (n=338)
Risk set (n=1923)
Fig 2 |Response rates and reasons for loss to follow-up
Table 2 | Patterns of cannabis use in relation to presence of psychotic symptoms* at T2 (3.
5 years after baseline) and T3 (8.4 years after baseline) in risk set (n=1923). Figures are
numbers (percentage†) of participants
Cannabis use‡
Psychotic symptoms at T2 Psychotic symptoms at T3
Yes No Yes No
Baseline
Yes 81 (4) 166 (9) 42 (2) 205 (11)
No 355 (18) 1321 (69) 189 (10) 1487 (77)
T2
Yes 126 (7) 267 (14) 69 (4) 324 (17)
No 310 (16) 1220 (64) 162 (8) 1368 (71)
*Any psychotic symptom lifetime (T2) and interval (T3) as assessed with M-CIDI (G) section.
†Some percentages do not total 100 because of rounding.
‡On more than five occasions as assessed with M-CIDI (L) section.
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psychologist invited participants to read a list of all the
psychotic experiences and then asked them whether
they ever experienced such symptoms (list and phras-
ing available on request). All these psychosis items
were rated as absent or present. Thus, all the psychosis
DIA-X/M-CIDI items used in the present study were
coded in a dichotomous manner without intermediate
levels. Psychotic symptoms at T2 accordingly referred
to lifetime occurrence of at least one positive rating on
any psychosis item in the G section; T3 psychotic
symptoms denote interval occurrence of at least one
positive rating on any psychosis item in this section.
Assessment of cannabis use
Cannabis use was assessed with the L-section of the
DIA-X/M-CIDI at all three assessments. The question
“Have you ever used cannabis five times or more?”
was used to define cannabis exposure. As with pre-
vious work in this sample,6 the CIDI cut off of use of
five times or more was used to define cannabis expo-
sure (yes versus no). Thus, at baseline, cannabis use
was defined as lifetime use of cannabis of five times
or more (“baseline cannabis use,” dichotomously
defined yes versus no). At T2, and similarly at T3, can-
nabis use was defined as interval use of cannabis of five
times or more, during the intervals of baseline toT2
and T2 to T3, respectively (T2 cannabis use, T3 canna-
bis use, both dichotomously defined yes versus no). As
assessment of frequency of cannabis use differed
between time points (for instance, at baseline: How
often do you use cannabis on a five point scale ranging
from less than monthly to almost daily?; at T2: How
many times have you used cannabis since the last
assessment?), the frequency variable was not included
in the analyses.
Statistical analyses
We used Stata, release 10.0 (StataCorp, College Sta-
tion, TX) for data analysis and expressed associations
as odds ratios from logistic regression models.
All analyses were a priori adjusted for age at baseline
(in years), sex (0=female, 1=male), socioeconomic sta-
tus (lower, middle, upper, other, as assessed at base-
line), use of other drugs at baseline and T2, childhood
trauma (that is, trauma before the age of 14 as assessed
at baseline),27 and urban/rural environment.28 29 The
variable use of other drugs included psychostimulants,
sedatives, opiates, cocaine, phencyclidine, and
psychedelic drugs and refers to CIDI rated use of five
times or more (lifetime or interval use at baseline and
T2 respectively) of any of these drugs, as assessed with
the L section of the M-CIDI. Childhood trauma refers
to experience of any traumatic experience during
childhood as assessed with the N section of the M-
CIDI at baseline and was dichotomously defined as
present or absent. Fisher and colleagues have shown
that self report questionnaires constitute a valid
method of assessing childhood trauma in individuals
presenting with psychotic features.30 Urban/rural
environment was assessed at baseline by retrieving
data on place of residence from the population registry
offices of the city and the 29 counties of Munich and
was defined as either living in the city of Munich
(10 559 people per km2) or in the rural surroundings
(1432 people per km2) at baseline.
To examine whether associations between cannabis
use and psychotic symptoms were independent of
other psychiatric diagnoses at baseline,we additionally
adjusted analyses for any psychiatric diagnosis other
than psychosis at baseline. We used a dichotomous
variable of any psychiatric diagnosis (present versus
absent), summarising main psychiatric diagnoses
other than psychosis at baseline (such as major depres-
sive disorder, hypomania, dysthymic disorder, bipolar
disorder, panic disorder, obsessive compulsive disor-
der, post-traumatic stress disorder, conversion disor-
der, somatisation disorder, eating disorders).
We carried out sensitivity analyses to investigate
whether attrition occurred at random and to assess
potential bias introduced by missing data. This was
done by multiple imputation of missing values with
the ICE routine in Stata 11.1. This method imputes
several alternative versions of the complete dataset
from the available data.
Incident use of cannabis and incidence of psychotic
symptoms
We used logistic regression analyses to investigate the
association between incident cannabis use from base-
line to T2 and incident psychosis outcome from T2 to
T3 (see fig 1, top). To investigate the true incidence of
psychotic symptoms after cannabis use, rather than
persistence of pre-existing psychotic experiences, we
excluded from the analysis individuals who had
admitted to lifetime presence of any psychotic symp-
tom at T2 (n=574, 23%). We also excluded all indivi-
duals with cannabis use at baseline, thus including only
individuals with new cannabis exposure between base-
line and T2.
We investigated reverse causality (that is, self medi-
cation) by testing the association between psychosis at
baseline-T2 and cannabis use at T2-T3 in those who
had not used cannabis at both baseline and T2.
Cannabis use and risk of persistent psychotic symptoms
We calculated a dichotomous persistence variable (no
persistence versus persistence), with no persistence
referring to experience of psychotic symptoms either
never or only once (at T2 or T3) and persistence
Table 3 | Association between incident cannabis use at T2 (3.
5 years after baseline) and incident psychotic experiences at
T3 (8.4 years after baseline) Figures are odds ratios (95%
confidence intervals) and P values
Cannabis use at T2
Risk of psychotic experiences at T3
Unadjusted Adjusted*
Whole sample 1.8 (1.3 to 2.4), <0.001 1.5 (1.1 to 2.1), 0.018
After exclusion† 2.1 (1.3 to 3.4), 0.004 1.9 (1.1 to 3.1), 0.021
*Adjusted for age, sex, socioeconomic status, use of other drugs,
childhood trauma, and urban/rural environment.
†Excludes individuals with baseline cannabis use and pre-existing
psychotic symptoms.
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referring to experience of psychotic symptoms at both
T2 and T3. To investigate whether different levels of
exposure to cannabis affected persistence of psychotic
symptoms differentially, we calculated a categorical
cannabis continuation variable (0 = never used canna-
bis; 1= cannabis use at baseline but not at T2; 2 = can-
nabis use at T2 but not at baseline, 3 = cannabis use at
both baseline andT2).We used logistic regression ana-
lyses to investigate the association between cannabis
continuation and psychosis persistence (fig 1 bottom).
RESULTS
Sample
A total of 2210 individuals completed the T3 assess-
ment; information on substance use and psychotic
symptoms was missing for 287 participants, resulting
in a final risk set for analysis of 1923 individuals, of
whom 926 (48%) were men (fig 2). Mean age was
18.3 (SD 3.3) at baseline, 21.8 (SD 3.4) at T2, and
26.6 (SD 3.5) at T3. Table 1 gives further characteris-
tics of participants.
At baseline, 247 participants reported using canna-
bis (13% lifetime use). Of those, 56 participants (23%)
used cannabis almost every day, 69 (28%) reported
weekly use, 57 (23%) used cannabis monthly, and 65
(26%) reported using cannabis less than once a month.
At T2, 392 participants reported using cannabis (20%
interval use). The mean frequency of those who
reported cannabis use at T2 was 130 times within the
period from baseline to T2 (range 5-997). Psychotic
symptoms were reported by 436 participants (23%) at
T2 (lifetime) and by 231 participants (12%) at T3 (inter-
val). Table 2 summarises patterns of cannabis use in
relation to psychotic symptoms.
Incident cannabis use and incidence of psychotic
symptoms
The incidence rate of psychotic symptoms over the
period from baseline to T2 was 31% (152) in exposed
individuals and 20% (284) in non-exposed individuals;
over the period from T2 to T3 these rates were 14%
(108) and 8% (49), respectively.
Lifetime cannabis use as assessed at T2 significantly
increased the risk of psychotic experiences at T3
(adjusted odds ratio 1.5, 95% confidence interval 1.1
to 2.1; P=0.018; tables 3 and 4). After we excluded
all individuals who had used cannabis at baseline and
had reported psychotic experiences at T2, incident
cannabis use over the period from baseline to T2 simi-
larly increased the risk for incident psychotic experi-
ences between T2 and T3 (1.9, 1.1 to 3.1, P=0.021).
Results were unchanged after additional adjustment
for any psychiatric diagnosis other than psychosis at
baseline (1.9, 1.1 to 3.1; P=0.020).
There was no evidence for self medication effects, as
psychotic experiences at T2 did not predict incident
cannabis use between T2 and T3 (0.8, 0.6 to 1.2;
P=0.3).
Cannabis use and persistence of psychotic experiences
Analyses showed a significant association between
continuation of cannabis use and risk of persistence
of psychotic experiences (adjusted χ² 16.22, P=0.001;
tables 4 and 5). After adjustment for age, sex, socio-
economic status, use of other drugs at baseline and T2,
urban/rural environment, childhood trauma, and
occasional cannabis use (cannabis use at either baseline
or T2, exposure states 1 and 2), effect sizes were atte-
nuated, with significance only for the combination of
cannabis use at both baseline and T2 (exposure state 3;
adjusted odds ratio 2.2, 1.2 to 4.2; P=0.016).Additional
adjustment for any psychiatric diagnosis other than
psychosis at baseline occasioned a slight reduction in
the association between cannabis use at both baseline
and T2 and the risk for persistence of psychotic symp-
toms (2.0, 1.0 to 3.8; P=0.037).
Missing data
Imputation of 20 datasets with the ICE routine in Stata
11.1, which imputes multiple alternatives based on
available data, showed that the association between
continued cannabis use and the risk of persistence of
psychotic symptoms remained significant (adjusted χ²
16.65; P=0.001). Again, the strongest association was
found for exposure state 3 (that is, cannabis use at both
baseline andT2), with an adjusted odds ratio of 2.0 (1.1
to 3.7; P=0.028).
DISCUSSION
This 10 year follow-up study showed that incident can-
nabis use significantly increased the risk of incident
psychotic experiences. The association was indepen-
dent of age, sex, socioeconomic status, use of other
drugs, urban/rural environment, and childhood
trauma; additional adjustment for other psychiatric
diagnoses similarly did not change the results. There
was no evidence for selfmedication effects as psychotic
experiences did not predict later cannabis use. The
results thus help to clarify the temporal association
between cannabis use and psychotic experiences by
systematically addressing the issue of reverse causality,
given that the long follow-up period allowed exclusion
of all individuals with pre-existing psychotic experi-
ences or pre-existing cannabis use. In addition, canna-
bis use was confirmed as an environmental risk factor
impacting on the risk of persistence of psychotic
experiences (fig 3).
Table 4 | Course of psychotic experiences in relation to level
of continued cannabis use at T2 (3.5 years after baseline)
and T3 (8.4 years after baseline). Figures are numbers
(percentages) of participants
Cannabis continuation
Psychotic experiences at follow-up
None At T2 or T3 At T2 and T3
No use 1071 (75) 303 (21) 64 (4)
At baseline but not at T2 59 (64) 25 (27) 8 (9)
At T2 but not at baseline 144 (60) 75 (32) 19 (8)
At baseline and T2 90 (58) 48 (31) 17 (11)
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The mechanism behind the association
We investigated the association between cannabis use
and risk of psychosis by analysing the expression of
psychotic experiences. Psychotic experiences share
many characteristics with clinically relevant psychosis,
such as demographic, environmental, and genetic
risks, and are thought to represent a behavioural mar-
ker for psychosis liability.18 31 32 Psychotic experiences
are a common and generally transitory phenomenon
in the general population, that, nevertheless, might
become abnormally persistent and progress to clinical
psychotic disorder if combinedwith exposure to envir-
onmental risks.19 33 34 Our study confirmed cannabis as
an environmental risk factor, impacting on risk of psy-
chosis by increasing the risk of incident psychotic
experiences, and, if use continues over time, increasing
the risk of persistent psychotic experiences.
The finding that longer exposure to cannabis was
associatedwith greater risk for persistence of psychotic
experiences is in linewith an earlier study showing that
continued cannabis use over time increases the risk for
psychosis in a dose-response fashion.5 This is also in
agreement with the hypothesis that a process of sensi-
tisation might underlie emergence and persistence of
psychotic experiences35 as an indicator of liability to
psychotic disorder.18 31 Sensitisation refers to the phe-
nomenon that repeated exposure to an (environmen-
tal) stressor leads to progressively greater responses
over time.35-38 In rats, repeated exposure to THC
(delta-9-tetrahydrocannabinol, the main psychoactive
component of cannabis) induces behavioural sensitisa-
tion: rats pre-treated with increasing doses of THC
show greater behavioural (locomotor) responses to a
THC challenge after a 14 day washout period than
THC naive rats.39 40 In humans, however, direct evi-
dence for cannabis sensitisation is lacking. As our
study showed that the risk of persistent psychotic
experiences increases with longer periods of cannabis
exposure, we suggest that a process of sensitisation
underlies the association between cannabis and
psychosis.32
Methodological issues
The results should be interpreted in the light of several
limitations. Firstly, information on substance use and
psychosis outcome was acquired with the DIA-X/M-
CIDI, which essentially provides self reported infor-
mation. The interview was conducted face to face by
clinical psychologists, however, who were allowed to
followupwith clinical questioning to ensure systematic
and valid assessment of outcomes and can therefore be
assumed to yield better and more valid results than a
self report questionnaire. Secondly, the analyses were
not directly adjusted for the possible confounding
effects of a family history of psychosis as this informa-
tion was not available in the EDSP data. Previous
research has shown that associations between cannabis
use and psychotic symptoms are not reducible to
family history of psychosis41 42 and that genetic liability
for psychotic disorder does not predict cannabis use.43
In addition, individuals with a family history of psy-
chosis reportmore positive symptoms than individuals
without such predisposition.44 45 As we excluded all
individuals with at least one T2 lifetime psychotic
symptom from the analysis, the possible confounding
effect of family history for psychosis was indirectly
adjusted for to a degree. Furthermore, we used a rather
broad outcomemeasure, defined as aminimumof one
positive rating on a G section item, representing psy-
chotic experiences rather than clinically relevant psy-
chotic disorder. It has been shown, however, that
psychotic experiences show continuity with psychotic
disorders such as schizophrenia.18 46 In addition, given
that fact transient psychotic experiences might, under
certain circumstances, become abnormally persistent,
giving rise to clinical psychotic disorder,15 17 19 psycho-
tic experiences represent an important phenotype for
the investigation of mechanisms and pathways by
which environmental risk factors such as cannabis
impact on psychosis risk. A further limitation concerns
the use of the G section of the DIA-X/M-CIDI. This
section was administered at T2 to assess lifetime occur-
rence of symptoms, which represents a long period for
retrospective assessment of psychotic phenomena,
possibly resulting in false negative results. As we
excluded participants with T2 lifetime experience of
psychotic symptoms from the analyses, under-report-
ing would have resulted in false negative results being
incorrectly retained in the analyses. It is unlikely that
Le
ve
l o
f p
sy
ch
os
is
Birth Adolescence Adulthood Old age
None
Psychotic
disorder
Subclinical
“schizotypal”
Person A
Person B
Person C
Cannabis exposure
Fig 3 | Cannabis-psychosis persistence model. Person A has
normal developmental expression of subthreshold psychotic
experiences that are mild and transient. Person B has similar
expression but longer persistence because of additional
environmental exposure (here cannabis). Person C has
prolonged persistence and subsequent transition to clinical
psychotic disorder because of repeated environmental
exposure—that is, repeated cannabis use
Table 5 | Association between continued use of cannabis (over period from baseline to T2)
and persistence* of psychotic experiences over period from T2 to T3. Figures are odds ratios
(95% confidence intervals) and P values
Cannabis continuation
Risk of persistence of psychotic experiences
Unadjusted Adjusted†
No use 1 1
At baseline but not at T2 2.0 (0.95 to 4.4), 0.068 2.1 (0.9 to 4.7), 0.078
At T2 but not at baseline 1.9 (1.1 to 3.2), 0.022 1.4 (0.8 to 2.5), 0.202
At baseline and T2 2.6 (1.5 to 4.6), 0.001 2.2 (1.2 to 4.2), 0.016
*Persistence of psychotic experiences; present at T2 and T3.
†Adjusted for age, sex, socioeconomic status, use of other drugs baseline and T2, childhood trauma, and
urban/rural environment.
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under-reporting would have occurred as a function of
cannabis use, which could have resulted in biased esti-
mates. In addition, 23% of participants reported life-
time subclinical psychotic symptoms at T2, which is
in keeping with the estimated 15-28% rate of subclini-
cal psychotic symptoms in the general population.47
Therefore, the influence of under-reporting is prob-
ably limited. Finally, as the time between follow-up
visits was four years on average, selective recall could
have influenced the results. Spurious findings could
have arisen if those with psychotic symptoms had bet-
ter recall of earlier cannabis use. Given the well known
link between psychosis liability and cognitive altera-
tions, including impaired memory, any influence of
selective recall would probably have been conserva-
tive rather than anti-conservative.
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